{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:34:06Z","timestamp":1791221646463,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T00:00:00Z","timestamp":1450742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/bjc.2015.422","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T21:00:33Z","timestamp":1450818033000},"page":"7-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies"],"prefix":"10.1038","volume":"114","author":[{"given":"K","family":"Yong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Cavet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Akinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Oakervee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Cavenagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,22]]},"reference":[{"issue":"18","key":"BFbjc2015422_CR1","doi-asserted-by":"publisher","first-page":"4152","DOI":"10.1200\/JCO.2005.00.612","volume":"23","author":"U Banerji","year":"2005","unstructured":"Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I (2005a) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23 (18): 4152\u20134161.","journal-title":"J Clin Oncol"},{"issue":"19","key":"BFbjc2015422_CR2","doi-asserted-by":"publisher","first-page":"7023","DOI":"10.1158\/1078-0432.CCR-05-0518","volume":"11","author":"U Banerji","year":"2005","unstructured":"Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P (2005b) Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 11 (19): 7023\u20137032.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"BFbjc2015422_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Samson D, Reece D, Apperley J, Bj\u00f6rkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102 (5): 1115\u20131123.","journal-title":"Br J Haematol"},{"issue":"12","key":"BFbjc2015422_CR4","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukaemia: revised guidelines for diagnosis and treatment. Blood 87 (12): 4990\u20134997.","journal-title":"Blood"},{"issue":"4","key":"BFbjc2015422_CR5","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1038\/bcj.2012.13","volume":"2","author":"T Ishii","year":"2012","unstructured":"Ishii T, Seike T, Nakashima T, Juliger S, Maharaj L, Soga S, Akinaga S, Cavenagh J, Joel S, Shiotsu Y (2012) Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J 2 (4): e68.","journal-title":"Blood Cancer J"},{"issue":"11","key":"BFbjc2015422_CR6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood.V112.11.1625.1625","volume":"112","author":"S Juliger","year":"2008","unstructured":"Juliger S, Nakashima T, Maharaj L, Ishii T, Nakagawa H, Kanda Y, Oakerveel H, Cavenagh J, Akinaga S, Shiotsu Y, Joel S (2008) A novel heat shock protein (Hsp) 90 inhibitor KW-2478 shows activity in B-cell malignancies in vitro and in vivo. Blood 112 (11): 574 (abstract 1625).","journal-title":"Blood"},{"issue":"2","key":"BFbjc2015422_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1023\/B:DOOP.0000036793.44912.45","volume":"108","author":"MF Marmor","year":"2004","unstructured":"Marmor MF, Holder GE, Seeliger MW, Yamamoto S International Society for Clinical Electrophysiology of Vision (2004) Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108 (2): 107\u2013114.","journal-title":"Doc Ophthalmol"},{"issue":"14","key":"BFbjc2015422_CR8","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1200\/JCO.2010.34.0760","volume":"29","author":"CS Mitsiades","year":"2011","unstructured":"Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, Richardson PG (2011) Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 29 (14): 1916\u20131923.","journal-title":"J Clin Oncol"},{"issue":"3","key":"BFbjc2015422_CR9","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2005-03-1158","volume":"107","author":"CS Mitsiades","year":"2006","unstructured":"Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC (2006) Antimyeloma activity of heat shock protein-90 inhibition. Blood 107 (3): 1092\u20131100.","journal-title":"Blood"},{"issue":"22","key":"BFbjc2015422_CR10","doi-asserted-by":"publisher","first-page":"14374","DOI":"10.1073\/pnas.202445099","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99 (22): 14374\u201314379.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 1","key":"BFbjc2015422_CR11","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1053\/j.seminhematol.2012.05.004","volume":"49","author":"P Moreau","year":"2012","unstructured":"Moreau P (2012) The future of therapy for relapsed\/refractory multiple myeloma: emerging agents and novel treatment strategies. Semin Hematol 49 (Suppl 1): S33\u2013S46.","journal-title":"Semin Hematol"},{"issue":"10","key":"BFbjc2015422_CR12","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1158\/1078-0432.CCR-09-3112","volume":"16","author":"T Nakashima","year":"2010","unstructured":"Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, Akinaga S, Soga S, Shiotsu Y (2010) New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res 16 (10): 2792\u20132802.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"BFbjc2015422_CR13","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1158\/1078-0432.CCR-11-0821","volume":"17","author":"A Rajan","year":"2011","unstructured":"Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G (2011) A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 17 (21): 6831\u20136839.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"BFbjc2015422_CR14","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1158\/1078-0432.CCR-12-3404","volume":"19","author":"C Sessa","year":"2013","unstructured":"Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA, Akimov M, Quadt C, Fernandez-Ibarra C, Lu H, Bailey S, Chica S, Banerji U (2013) First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 19 (13): 3671\u20133680.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2015422_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0065-230X(06)95009-X","volume":"95","author":"S Sharp","year":"2006","unstructured":"Sharp S, Workman P (2006) Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 95: 323\u2013348.","journal-title":"Adv Cancer Res"},{"issue":"4","key":"BFbjc2015422_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/leu.2011.279","volume":"26","author":"S Sinha","year":"2012","unstructured":"Sinha S, Lacy M, Mikhael J, Hayman S, Buadi F, Detweiler-Short K, Dispenzieri A, Gertz M, Dingli D, Rajkumar SV, Kumar SK (2012) Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. Leukemia 26 (4): 839\u2013841.","journal-title":"Leukemia"},{"issue":"8","key":"BFbjc2015422_CR17","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/leu.2008.111","volume":"22","author":"T St\u00fchmer","year":"2008","unstructured":"St\u00fchmer T, Z\u00f6llinger A, Siegmund D, Chatterjee M, Grella E, Knop S, Kort\u00fcm M, Unzicker C, Jensen MR, Quadt C, Ch\u00e8ne P, Schoepfer J, Garc\u00eda-Echeverr\u00eda C, Einsele H, Wajant H, Bargou RC (2008) Signalling profile and antitumor activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 22 (8): 1604\u20131612.","journal-title":"Leukemia"},{"issue":"Suppl","key":"BFbjc2015422_CR18","doi-asserted-by":"crossref","first-page":"abstract 3086","DOI":"10.1200\/jco.2012.30.15_suppl.3086","volume":"30","author":"D Zhou","year":"2012","unstructured":"Zhou D, Teofilovici F, Liu Y, Ye J, Ying W, Ogawa LS, Inoue T, Lee W, Adjiri-Awere A, Kolodzieyski L, Tatsuta N, Wada Y, Sonderfan AJ (2012) Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors. J Clin Oncol 30 (Suppl): abstract 3086.","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2015422.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2015422","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2015422.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:31:11Z","timestamp":1684416671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2015422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,22]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["BFbjc2015422"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2015.422","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,22]]},"assertion":[{"value":"6 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D Nakashima and S Akinaga are employees of Kyowa Hakko Kirin Co. Ltd (Tokyo and USA). The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}